Newswires
Titan Pharma Completes Buprenorphine Implant Phase 3 Trials

04/20/2012 -ATIN- Titan Pharmaceuticals (OBB: TTNP) a tiny, highly speculative Bulletin Board (penny) stock drug developer has announced what it says are positive results from Phase 3 clinical trials for its brand named Probuphine, which is a buprenorphine implant designed for very long term treatment of opioid dependence. Just two weeks ago, Titan announced its intention to raise $5.5M in a new stock offering. England's Reckitt Benckiser, which early on sponsored the pioneering research of Dr. Ed Johnson into buprenorphine, is the most successful of a growing, but still tiny relative to the huge size of drug industry, group of drug developers that are seeking to provide pharmacological treatments for a disease that until very recently had depended almost entirely on behavioral therapeutic interventions. Reckitt's buprenorphine-based Suboxone, which has been slated to go generic, is the most successful addiction drug in history, apart from methadone, with sales last year in excess of $350M. Alkermes is another member of this growing drug company group, but has had very limited success with its enormously expensive - $7,000.00 for a monthly injection - and marginally effective VIVITROL despite spending huge sums, well over $300M, marketing the drug. According to research reports, there are at least 36 addiction treatment compounds in various stages of testing by commercial drug developers worldwide, with government sponsored entities conducting many addictional investigations.  

 POST YOUR COMMENTS BELOW..start a debate!

Read More Newswire Stories

Trackback(0)
Comments (1)Add Comment
Incorrect information!
written by Kathy, May 01, 2013
Where do you get, "enormously expensive - $7,000.00 for a monthly injection" ????? That is not accurate
report abuse
vote down
vote up
Votes: +0

Write comment
quote
bold
italicize
underline
strike
url
image
quote
quote
smaller | bigger

busy
 

Recent Print Issue: Sept 2015 | Subscribe Now!

Special Report
Austin's MAP Looking to Future
Outcomes
andValue-Based Compensation
Growth Through Licensing

On the Cover: Jacob Levinson
Founder, CEO MAP

Click here to read the digital
print edition of TM.

Follow Treatment Magazine on Twitter!
Become a fan of Treatment Magazine on Facebook!